Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	31.07	29.87	19.13	15.24	8.61
Research & Development	141.8	85.28	81.76	64.92	37.05
Operating Expenses	172.87	115.16	100.89	80.15	45.65
Operating Income	-172.87	-115.16	-100.89	-80.15	-45.65
Interest Expense / Income	3.1	0.74	0	0	0
Other Expense / Income	-24.21	-3.86	-0.11	-0.95	-1.9
Pretax Income	-151.76	-112.03	-100.78	-79.21	-43.76
Net Income	-151.76	-112.03	-100.78	-79.21	-43.76
Shares Outstanding (Basic)	53	39	35	31	15
Shares Outstanding (Diluted)	53	39	35	31	15
Shares Change	34.84%	11.94%	10.69%	108.77%	14474.75%
EPS (Basic)	-2.89	-2.87	-2.89	-2.52	-2.90
EPS (Diluted)	-2.89	-2.87	-2.89	-2.52	-2.90
Free Cash Flow	-145.37	-92.52	-79.68	-70.95	-35.63
Free Cash Flow Per Share	-2.77	-2.37	-2.29	-2.25	-2.36
EBITDA	-148.4	-111.03	-100.53	-78.99	-43.76
Depreciation & Amortization	0.26	0.26	0.24	0.21	0
EBIT	-148.66	-111.29	-100.78	-79.21	-43.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).